P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations

S Rastogi, S Bosnic-Antievich, I Pavord, N Roche, D Halpin, L Bjermer, O S Usmani, G Brusselle, S Wan Yau Ming, S Halim, G Gopalan, D Price

Research output: Contribution to journalAbstract


Introduction and Objectives Blood eosinophil counts (BltextendashEos) and fractional exhaled nitric oxide concentrations (FeNO) are established biomarkers in asthma. While patients with raised BltextendashEos are at increased risk of asthma exacerbations, it is unclear whether raised FeNO is associated with further increased risk. We sought to determine if raised BltextendashEos combined with raised FeNO was associated with increased frequency of asthma exacerbations.Methods This was a cross-sectional study of data from the Optimum Patient Care Research Database. Patients included were aged 18textendash80 years with >=1 year of continuous electronic health records prior to their most recent FeNO readings, had evidence of asthma, had received >=1 inhaled corticosteroid prescription, and had BltextendashEos recorded within 5 years of FeNO reading. Cohorts were determined by: BltextendashEos raised (>=0.25texttimes109/L, a cutoff representing the sample mean) and not raised (lt;0.25texttimes109/L) and, FeNO raised (>=35 ppb) and not raised (lt;35 ppb). Patients were directly matched on age, sex, and smoking status. Patients with (i) raised BltextendashEos and not raised FeNO, (ii) raised FeNO and not raised BltextendashEos, or (iii) both biomarkers raised were compared with reference patients (neither biomarker raised). Comparison of exacerbations (evidenced by acute oral corticosteroid prescription or unplanned asthma-related hospital attendance) was conducted using conditional Poisson regression.Results The unmatched study population consisted of 610 patients (mean age 52, 38% male, 46% non-smokers). With 1:1 matching, both the (i) raised BltextendashEos and not raised FeNO cohort (n=186) and the (ii) raised FeNO and not raised BltextendashEos cohort (n=98) demonstrated a trend toward greater exacerbation rates (unadjusted rate ratio: 1.41 [95% CI 0.91, 2.19] and 1.35 [95% CI 0.99 1.84], respectively) vs. reference group. Importantly, however, when both biomarkers were raised (n=53), a significantly greater exacerbation rate was observed (1.72 [95% CI 1.00, 2.93]).Conclusion The combination of raised FeNO and raised BltextendashEos was associated with a greater exacerbation rate compared with neither biomarker raised. FeNO and BltextendashEos are simple primary care measurements that could reliably predict exacerbation risk for asthma patients. This should be confirmed prospectively in larger populations.Please refer to page A258 for declarations of interest in relation to abstract P198.
Original languageEnglish
Pages (from-to)A190
Issue numberSuppl 3
Early online date15 Nov 2017
Publication statusPublished - 1 Dec 2017

Fingerprint Dive into the research topics of 'P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations'. Together they form a unique fingerprint.

  • Cite this

    Rastogi, S., Bosnic-Antievich, S., Pavord, I., Roche, N., Halpin, D., Bjermer, L., Usmani, O. S., Brusselle, G., Ming, S. W. Y., Halim, S., Gopalan, G., & Price, D. (2017). P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations. Thorax, 72(Suppl 3), A190. https://doi.org/10.1136/thoraxjnl-2017-210983.340